5-HT2A: Its role in frontally mediated executive function and related psychopathology
dc.contributor.author | Stein D.J. | |
dc.contributor.author | Hemmings, Sian M. J. | en_ZA |
dc.contributor.author | Moolman-Smook H. | |
dc.contributor.author | Audenaert K. | |
dc.date.accessioned | 2011-05-15T16:01:24Z | |
dc.date.available | 2011-05-15T16:01:24Z | |
dc.date.issued | 2007 | |
dc.description.abstract | Serotonin (5-HT)2A receptors are widely distributed, with high levels in the frontal cortex, where postsynaptic activation may increase activity in pyramidal glutamatergic neurons and mediate various executive functions. More specifically, reciprocal cortical-raphe pathways may allow the ventral prefrontal cortex to inhibit stress-induced neural activity in the brainstem when stressors are perceived as controllable. However, early adversity and negative attitudes may be associated with higher frontal 5-HT2A receptor levels and greater risk for stress-induced psychopathology, and certain 5-HT2A gene variants have been associated with increased risk for impulsive behavior. Conversely, many antidepressants result in decreased levels of 5-HT2A receptor levels, and blockade of 5-HT2A receptors has proven useful in the treatment of a number of psychiatric disorders. | |
dc.description.version | Article | |
dc.identifier.citation | CNS Spectrums | |
dc.identifier.citation | 12 | |
dc.identifier.citation | 7 | |
dc.identifier.issn | 10928529 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/11957 | |
dc.subject | antidepressant agent | |
dc.subject | glucocorticoid | |
dc.subject | mianserin | |
dc.subject | mirtazapine | |
dc.subject | nefazodone | |
dc.subject | serotonin 2A receptor | |
dc.subject | serotonin 2B receptor | |
dc.subject | serotonin 2C receptor | |
dc.subject | serotonin uptake inhibitor | |
dc.subject | trazodone | |
dc.subject | allele | |
dc.subject | article | |
dc.subject | binding site | |
dc.subject | case report | |
dc.subject | clinical feature | |
dc.subject | diagnostic and statistical manual of mental disorders | |
dc.subject | drug mechanism | |
dc.subject | drug withdrawal | |
dc.subject | gene expression | |
dc.subject | genetic variability | |
dc.subject | genotype | |
dc.subject | human | |
dc.subject | impulsiveness | |
dc.subject | liver toxicity | |
dc.subject | male | |
dc.subject | mental disease | |
dc.subject | pessimism | |
dc.subject | priority journal | |
dc.subject | recurrent disease | |
dc.subject | risk factor | |
dc.subject | sexual dysfunction | |
dc.subject | signal transduction | |
dc.subject | single nucleotide polymorphism | |
dc.subject | upregulation | |
dc.subject | attitude | |
dc.subject | cognitive defect | |
dc.subject | frontal lobe | |
dc.subject | major depression | |
dc.subject | mental stress | |
dc.subject | metabolism | |
dc.subject | pathophysiology | |
dc.subject | positron emission tomography | |
dc.subject | psychological aspect | |
dc.subject | Attitude | |
dc.subject | Cognition Disorders | |
dc.subject | Depressive Disorder, Major | |
dc.subject | Frontal Lobe | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Positron-Emission Tomography | |
dc.subject | Receptor, Serotonin, 5-HT2A | |
dc.subject | Serotonin Uptake Inhibitors | |
dc.subject | Stress, Psychological | |
dc.subject | Trazodone | |
dc.title | 5-HT2A: Its role in frontally mediated executive function and related psychopathology | |
dc.type | Article |